Clinical Trials Logo

Clinical Trial Summary

Carbon monoxide (CO) poisoning results in high morbidity and mortality worldwide. CO is described as a "silent killer" because CO is colorless, odorless, and tasteless but highly toxic. The diagnosis of acute CO poisoning depends on the history of exposure to a source of fire in a closed space along with the clinical and laboratory findings. The pathophysiology of CO poisoning is not fully understood; however, it is proved that CO induces hypoxia by forming carboxyhemoglobin (COHb) and shifting the oxygen dissociation curve to the left. The molecular mechanisms of CO poisoning include oxidative injury through the generation of free radicals. In addition, oxygen therapy might enhance the reactive oxygen species (ROS) production and result in reperfusion injury. Free radicals could induce a serious impact on vital organs, including the heart, and brain. L-Carnitine is an endogenous mitochondrial constituent that contributes to normal mitochondrial activities. L-Carnitine is an antioxidant with potent ROS scavenging ability. ROS-mediated pathology of CO suggests that antioxidants are potentially useful agents in the alleviation of CO toxicity. Thus, the current study will investigate the therapeutic efficacy of L-Carnitine in improving the prognosis of acute CO poisoning. The current clinical trial will include patients with moderate and severe acute carbon monoxide poisoning according to Poisoning Severity Score.


Clinical Trial Description

A randomized clinical trial (phase II) will be conducted at Alexandria Main University Hospital. The total required sample size is 72. The sample size was calculated by G power 3.1.9.4 software program depending on the primary outcome. According to these assumptions: Effect size, defined as the difference between group 1 and group 2 in the mean troponin levels at 24 hr, was calculated according to Sun et al. (2011) and was 0.657, alpha error =0.05, power of 80%, allocation ratio 1:1. A 20% expected attrition was added to the sample size to account for loss to follow-up. So, the final sample size was 72; 36 patients per group. All patients will be subject to the following: 1. History taking: - Personal data: age, and sex. - Exposure-related data: circumstances of exposure, and time till hospitalization. - Past medical history. 2. Clinical assessment: - Glasgow coma scale, vital signs, and general examination. - Laboratory investigations: arterial blood gases (ABG), Carboxy hemoglobin level (COHb), and cardiac enzymes (CPK, CK-MB, Troponin). - Electrocardiogram (ECG). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05647707
Study type Interventional
Source Alexandria University
Contact Zahraa K Sobh, MD
Phone 01020744739
Email zahraa.sobh@alexmed.edu.eg
Status Not yet recruiting
Phase Phase 2
Start date December 15, 2022
Completion date August 1, 2023

See also
  Status Clinical Trial Phase
Completed NCT03669848 - Is Transcutaneous Carbon Monoxide Saturation of E-cigarette Users Comparable to That of Smokers?
Completed NCT04656912 - Hyperbaric Oxygen Therapy Initiation Time in Acute Carbon Monoxide Poisoning
Recruiting NCT04975867 - Adjunct Targeted Temperature Management in Acute Severe Carbon Monoxide Poisoning N/A
Terminated NCT01100515 - Hyperbaric Oxygen Therapy for Acute Domestic Carbon Monoxide (CO) Poisoning Phase 3
Terminated NCT01099995 - Hyperbaric Oxygen Therapy for Comatose Patients With Acute Carbon Monoxide Poisoning Phase 3
Terminated NCT03017742 - Utility of Non-invasive Carboxyhemoglobin and Total Hemoglobin Measurement in the Emergency Department
Terminated NCT01059708 - Outcome Following Carbon Monoxide Poisoning in Children N/A
Recruiting NCT05591300 - Microparticles Blood Level in Acute Carbon Monoxide Poisoning
Not yet recruiting NCT04475263 - Cognitive and Blood Biomarker Assessment After CO Exposure
Completed NCT03926494 - Carbon Monoxide-induced Coma: Prognostic Factors
Recruiting NCT02375126 - Normal Quantitative EEG (qEEG) Dataset
Completed NCT03342209 - Utility of High Flow Nasal Cannula in CO Toxicity N/A
Completed NCT00465855 - One vs. Three Hyperbaric Oxygen Treatments for Acute Carbon Monoxide Poisoning Phase 4
Recruiting NCT04490317 - CARbon monoxidE intoxiCatiOn in Korea: Prospective Cohort (CARE CO Cohort)
Withdrawn NCT04118491 - Hyperbaric Oxygen for Carbon Monoxide Induced Chronic Encephalopathy N/A
Unknown status NCT00841165 - Carbon Monoxide Monitoring and Emergency Treatment N/A
Withdrawn NCT00280579 - Cyanide Poisoning in Fire Victims N/A
Enrolling by invitation NCT02483650 - Hyperbaric Oxygen Therapy Registry
Completed NCT05088005 - Prognostic Biomarkers in CO Poisoning
Completed NCT03030833 - Dysfunctional Hemoglobin Pulse Oximetry N/A